1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Lupus Erythematosus - Pipeline Review, H2 2020, provides an overview of the Systemic Lupus Erythematosus (Immunology) pipeline landscape.
Systemic lupus erythematosus (SLE) is an autoimmune disease that causes a chronic inflammatory condition. The inflammation triggered by SLE affect many organs in the body, including skin, joints, kidneys, brain, and other organs. Several factors have been associated with the disease such as genetics, environment and gender and hormones. Symptoms can vary and can change over time. Common symptoms include severe fatigue, painful or swollen joints, headaches, rash on cheeks and nose called butterfly rash, hair loss and anemia.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Systemic Lupus Erythematosus - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Systemic Lupus Erythematosus (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Systemic Lupus Erythematosus (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Lupus Erythematosus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 7, 38, 23, 2, 77, 20 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 2, 1, 1, 13 and 2 molecules, respectively.
Systemic Lupus Erythematosus (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus (Immunology).
- The pipeline guide reviews pipeline therapeutics for Systemic Lupus Erythematosus (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Systemic Lupus Erythematosus (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Systemic Lupus Erythematosus (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Lupus Erythematosus (Immunology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Systemic Lupus Erythematosus (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionSystemic Lupus Erythematosus - Overview
Systemic Lupus Erythematosus - Therapeutics Development
Systemic Lupus Erythematosus - Therapeutics Assessment
Systemic Lupus Erythematosus - Companies Involved in Therapeutics Development
Systemic Lupus Erythematosus - Drug Profiles
Systemic Lupus Erythematosus - Dormant Projects
Systemic Lupus Erythematosus - Discontinued Products
Systemic Lupus Erythematosus - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Systemic Lupus Erythematosus, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Systemic Lupus Erythematosus - Pipeline by AbbVie Inc, H2 2020
- Systemic Lupus Erythematosus - Pipeline by ACEA Therapeutics Inc, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Akeso Inc, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Alexion Pharmaceuticals Inc, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Alpine Immune Sciences Inc, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Aluda Pharmaceuticals Inc, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Amgen Inc, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Apellis Pharmaceuticals Inc, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Apimeds Inc, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Aprilbio Co Ltd, H2 2020
- Systemic Lupus Erythematosus - Pipeline by APT Therapeutics Inc, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Asahi Kasei Pharma Corp, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Astellas Pharma Inc, H2 2020
- Systemic Lupus Erythematosus - Pipeline by AstraZeneca Plc, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Athos Therapeutics Inc, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Atlantic Bio Sci LLC, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Aurinia Pharmaceuticals Inc, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Avotres Inc, H2 2020
- Systemic Lupus Erythematosus - Pipeline by BellBrook Labs LLC, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Bio-Path Holdings Inc, H2 2020
- Systemic Lupus Erythematosus - Pipeline by BioAegis Therapeutics Inc, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Biocon Ltd, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Biogen Inc, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Biotest AG, H2 2020
- Systemic Lupus Erythematosus - Pipeline by BioTheryX Inc, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Boehringer Ingelheim International GmbH, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Boston Pharmaceuticals Inc, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Bristol-Myers Squibb Co, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Rheos Medicines Inc, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Sanofi, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Sareum Holdings Plc, H2 2020
- Systemic Lupus Erythematosus - Pipeline by SBI Biotech Co Ltd, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Sengenics Corp Pte Ltd, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Shanghai GeneChem Co Ltd, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Shanghai Junshi Bioscience Co Ltd, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, H2 2020
- Systemic Lupus Erythematosus - Pipeline by SinoMab Bioscience Ltd, H2 2020
- Systemic Lupus Erythematosus - Pipeline by StingInn LLC, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Suzhou Sinovent Pharmaceuticals Co Ltd, H2 2020
- Systemic Lupus Erythematosus - Pipeline by SynAct Pharma AB, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2020
- Systemic Lupus Erythematosus - Pipeline by TherapyX Inc, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Tonix Pharmaceuticals Holding Corp, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Twoxar Inc, H2 2020
- Systemic Lupus Erythematosus - Pipeline by UCB SA, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Vera Therapeutics Inc, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Viela Bio Inc, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Visterra Inc, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Voronoi Group, H2 2020
- Systemic Lupus Erythematosus - Pipeline by Xencor Inc, H2 2020
- Systemic Lupus Erythematosus - Pipeline by XTL Biopharmaceuticals Ltd, H2 2020
- Systemic Lupus Erythematosus - Pipeline by ZyVersa Therapeutics Inc, H2 2020
- Systemic Lupus Erythematosus - Dormant Projects, H2 2020
- Systemic Lupus Erythematosus - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Systemic Lupus Erythematosus, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc
- ACEA Therapeutics Inc
- Akeso Inc
- Alexion Pharmaceuticals Inc
- Alpine Immune Sciences Inc
- Aluda Pharmaceuticals Inc
- Amgen Inc
- Apellis Pharmaceuticals Inc
- Apimeds Inc
- Aprilbio Co Ltd
- APT Therapeutics Inc
- Asahi Kasei Pharma Corp
- Astellas Pharma Inc
- AstraZeneca Plc
- Athos Therapeutics Inc
- Atlantic Bio Sci LLC
- Aurinia Pharmaceuticals Inc
- Avotres Inc
- BellBrook Labs LLC
- Bio-Path Holdings Inc
- BioAegis Therapeutics Inc
- Biocon Ltd
- Biogen Inc
- Biotest AG
- BioTheryX Inc
- Boehringer Ingelheim International GmbH
- Boston Pharmaceuticals Inc
